FY2026 EPS Forecast for Edesa Biotech Decreased by Analyst

Edesa Biotech, Inc. (NASDAQ:EDSA) – Stock analysts at Zacks Research reduced their FY2026 earnings estimates for Edesa Biotech in a research note issued on Monday, March 2nd. Zacks Research analyst D. Bautz now expects that the company will post earnings per share of ($0.97) for the year, down from their previous estimate of ($0.94). The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Edesa Biotech in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Edesa Biotech has an average rating of “Hold” and a consensus target price of $5.00.

Edesa Biotech Trading Down 1.8%

Edesa Biotech stock opened at $4.27 on Wednesday. The business’s fifty day simple moving average is $1.46 and its two-hundred day simple moving average is $1.90. The company has a market capitalization of $35.65 million, a price-to-earnings ratio of -3.71 and a beta of 0.05. Edesa Biotech has a 12 month low of $0.72 and a 12 month high of $5.40.

Edesa Biotech (NASDAQ:EDSA) last announced its earnings results on Friday, February 13th. The company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). The business had revenue of $0.10 million for the quarter.

Hedge Funds Weigh In On Edesa Biotech

Several institutional investors have recently made changes to their positions in the business. State Street Corp purchased a new position in shares of Edesa Biotech in the fourth quarter worth approximately $27,000. Susquehanna International Group LLP bought a new position in Edesa Biotech in the third quarter worth approximately $36,000. Diadema Partners LP purchased a new position in shares of Edesa Biotech during the 4th quarter worth $77,000. Finally, DRW Securities LLC bought a new stake in shares of Edesa Biotech during the 4th quarter valued at $191,000. Institutional investors own 5.50% of the company’s stock.

Insider Activity

In related news, CEO Pardeep Nijhawan purchased 10,000 shares of Edesa Biotech stock in a transaction dated Tuesday, March 3rd. The stock was purchased at an average cost of $3.63 per share, for a total transaction of $36,300.00. Following the completion of the purchase, the chief executive officer directly owned 382,702 shares of the company’s stock, valued at $1,389,208.26. The trade was a 2.68% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have bought 60,571 shares of company stock worth $135,402. Company insiders own 22.60% of the company’s stock.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.